Dr. Tew Evaluates Avastin Treatment in Ovarian Cancer

Video

William P. Tew, MD, a Gynecologic Medical Oncologist at Memorial Sloan-Kettering Cancer Center in New York, evaluates bevacizumab (Avastin) as a treatment for women with ovarian cancer

William P. Tew, MD, a Gynecologic Medical Oncologist at Memorial Sloan-Kettering Cancer Center in New York, evaluates the angiogenesis inhibitor bevacizumab (Avastin) as a treatment for women with ovarian cancer, at the 2010 ASCO Annual Meeting.

Related Videos
Amma Asare, MD, PhD
Sundar Jagannath, MBBS
Elias Jabbour, MD
Rebecca Klisovic, MD
Axel Hauschild, MD, PhD, head, Skin Cancer Trial Center, University Hospital Schleswig-Holstein
David L. Porter, MD, director, Cell Therapy and Transplant, Jodi Fisher Horowitz Professor in Leukemia Care Excellence, Penn Medicine
Jubilee Brown, MD
Changchun Deng, MD, PhD
Laura J. Chambers, DO
Casey M. Cosgrove, MD
Related Content
Gursel Aktan, MD, vice president, global clinical development, Merck Research Laboratories

Adjuvant Pembrolizumab/Chemo Misses Primary End Point of DFS in High-Risk Endometrial Cancer

May 9th 2024
Article
Bradley J. Monk, MD, FACOG, FACS; Paolo Tarantino, MD

Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers

January 11th 2024
Podcast
R. Wendel Naumann, MD

Naumann Dives into Case-by-Case Decision-Making in Ovarian and Endometrial Cancer

May 8th 2024
Article
R. Wendel Naumann, MD

Naumann Discusses Notable Research Efforts in Endometrial Cancer

October 26th 2023
Podcast
Vaidehi Mujumdar, MD

Awareness and Early Detection Remain Key Issues in Ovarian Cancer

May 8th 2024
Article
R. Wendel Naumann, MD

Naumann Spotlights Expanding Arsenals and Evolving Decision-Making in Platinum-Resistant Ovarian Cancer

May 7th 2024
Article